Correction to: FLT3 inhibitor lestaurtinib plus chemotherapy for newly diagnosed KMT2A-rearranged infant acute lymphoblastic leukemia: Children’s Oncology Group trial AALL0631 (Leukemia, (2021), 35, 5, (1279-1290), 10.1038/s41375-021-01177-6)

Patrick A. Brown; John A. Kairalla; Joanne M. Hilden; Zo Ann E. Dreyer; Andrew J. Carroll; Nyla A. Heerema; Cindy Wang; Meenakshi Devidas; Lia Gore; Wanda L. Salzer; Naomi J. Winick; William L. Carroll; Elizabeth A. Raetz; Michael J. Borowitz; Donald Small; Mignon L. Loh; Stephen P. Hunger

ArticleOPEN ACCESS

Correction to: FLT3 inhibitor lestaurtinib plus chemotherapy for newly diagnosed KMT2A-rearranged infant acute lymphoblastic leukemia: Children’s Oncology Group trial AALL0631 (Leukemia, (2021), 35, 5, (1279-1290), 10.1038/s41375-021-01177-6)

Brown P
Kairalla J
Hilden J
et al.

Leukemia

DOI: 10.1038/s41375-021-01245-x

1Citations

9Readers

Abstract

Figure 3 of the original article was an incorrect version. The correct figure is: The original article has been updated. (Figure presented.).

Cite

CITATION STYLE

APA

Brown, P. A., Kairalla, J. A., Hilden, J. M., Dreyer, Z. A. E., Carroll, A. J., Heerema, N. A., … Hunger, S. P. (2021, May 1). Correction to: FLT3 inhibitor lestaurtinib plus chemotherapy for newly diagnosed KMT2A-rearranged infant acute lymphoblastic leukemia: Children’s Oncology Group trial AALL0631 (Leukemia, (2021), 35, 5, (1279-1290), 10.1038/s41375-021-01177-6). Leukemia. Springer Nature. https://doi.org/10.1038/s41375-021-01245-x

Correction to: FLT3 inhibitor lestaurtinib plus chemotherapy for newly diagnosed KMT2A-rearranged infant acute lymphoblastic leukemia: Children’s Oncology Group trial AALL0631 (Leukemia, (2021), 35, 5, (1279-1290), 10.1038/s41375-021-01177-6)

Abstract

Cite

Register to see more suggestions